ROSG 2 MM float. $4,000 per Cancer test, 1.2 Million potential patients.
ROSG:NASDAQ just got Medicare approval for cancer test. $4,000 per test.
In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the miRview® mets and miRview® mets² test, 60,000 from miRview® squamous, 60,000 from miRview® meso, 54,000 from miRview® kidney and more than 1 million patients worldwide from miRview® lung.
VRML went from pennies to $35 in a few months a few years back on optimism for a similar test, ROSH has much smaller float.
